QNRX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Quoin Pharmaceuticals Ltd DRC · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 4.45 USD
4.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -31.7% below the Trend Line and sits at 3.1% of its 52-week range. The latest completed week returned 4.0%, after a -2.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 18 out of 100
Latest Close 4.45 USD 31 Jul 2026
1W Return 4.0% latest completed week
4W Return -2.8% short-term follow-through
12W Return -25.0% quarterly tape
Trend Breadth 30.8% 16 of 52 weeks active
Volume Ratio 0.1x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.0% Latest completed week; four-week move -2.8%. Indicator stack 17/50 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 37.93% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 53/100 52 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -31.7% below the Trend Line and sits at 3.1% of its 52-week range. The latest completed week returned 4.0%, after a -2.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.1x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1312-week average 0.04

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.13Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.8% over four weeks, -25.0% over 12 weeks, and -34.8% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.0%
4W-2.8%
12W-25.0%
26W-38.3%
52W-34.8%
Active trend streak0 weeks
Active weeks in one year16
Trend breadth30.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.26Latest activity-pressure read.
Pressure change54.5%Four-week change in activity pressure.
Leadership-53.87Latest relative-leadership reading.
RS change4.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength42/100Blend of value, momentum, and quality. Underlying universe rank 59; rank 1 is best.
Value46/100Relative valuation strength. Underlying universe rank 55; rank 1 is best.
Quality44/100Profitability and accounting quality. Underlying universe rank 57; rank 1 is best.
Momentum46/100Medium-term price momentum. Underlying universe rank 55; rank 1 is best.
Growth46/100Revenue and earnings growth. Underlying universe rank 55; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-289.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 52 relevant articles.

10 positive · 38 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-89.4%Distance below the 52-week high.
13-week volatility7.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+17.6%Week of 13 Feb.
Worst week-19.3%Week of 27 Mar.
Latest week+4.0%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains5
Flat weeks0
Modest losses5
Sharp losses10
Recent vol7.1%13-week weekly-return volatility.
Base vol30.3%52-week weekly-return volatility.
Up/down split23/29Count of positive and negative weeks in the 52-week window.
Average skew18.4% / -11.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape19/100

Trend, activity pressure, participation, and risk combine to a 19/100 tape read.

 Indicator analysis11/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.13; No reversal markers Next-Week ExpectancyNegative 37.93%

Next-week expectancy is negative with a 37.93% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors43/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 51 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment53/100

Weighted news tone is neutral across 52 relevant articles.

Quoin Pharmaceuticals (NASDAQ:QNRX) gets FDA clearance for Phase 2 study in ultra-rare peeling skin syndrome Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20264.45 USD4.0%6.52 USD41.09 USD-0.26-53.8770.5KOff
24 Jul 20264.28 USD0.9%6.84 USD42.57 USD-0.37-55.7542.1KOff
17 Jul 20264.24 USD-4.7%7.16 USD44.23 USD-0.34-57.3493.7KOff
10 Jul 20264.45 USD-2.8%7.49 USD46.24 USD-0.44-57.60229.6KOff
3 Jul 20264.58 USD2.9%7.69 USD47.72 USD-0.56-56.16357.2KOff
26 Jun 20264.45 USD-4.3%7.94 USD48.92 USD-0.70-57.5613.2MOff
19 Jun 20264.65 USD10.7%8.52 USD50.23 USD-0.83-58.2397.7KOff
12 Jun 20264.20 USD-6.5%8.97 USD51.79 USD-0.87-61.76166.0KOff
5 Jun 20264.49 USD-11.3%9.33 USD53.19 USD-0.75-58.71168.6KOff
29 May 20265.06 USD6.1%9.48 USD54.45 USD-0.63-56.13163.7KOff
22 May 20264.77 USD-17.6%9.69 USD55.66 USD-0.56-57.94205.4KOff
15 May 20265.79 USD-2.4%9.96 USD56.78 USD-0.56-49.0163.7KOff
8 May 20265.93 USD-4.5%10.27 USD58.02 USD-0.69-48.3682.3KOff
1 May 20266.21 USD8.9%10.75 USD59.29 USD-0.90-43.24120.6KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.